Fig. 6: ESC-derived iNK cells inhibit the development of AML in vivo. | Cell Discovery

Fig. 6: ESC-derived iNK cells inhibit the development of AML in vivo.

From: Lateral plate mesoderm cell-based organoid system for NK cell regeneration from human pluripotent stem cells

Fig. 6

a Diagram of HL-60 cell xenogeneic B-NDG model for ESC-iNK cells against AML target in vivo. Mice were treated intravenously with PB-NK cells or ESC-iNK cells three times a week for 2 weeks. BLI was performed on Day 0, Day 7, Day 14, Day 21, Day 28, and Day 35. b Images of individual mouse radiance of the xenograft models (Tumor only, Tumor + PB-NK, and Tumor + ESC-iNK, n = 5 each group). The radiance indicates tumor burden. c Statistics of the total flux (p/s) of the xenograft models (mean ± SD, n = 5). One-way ANOVA and two-tailed independent t-test. d Kaplan-Meier survival curves of the xenograft models (P < 0.001, Log-rank test). Median survival times were shown.

Back to article page